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A B S T R A C T
The development of effective prophylactic strategies to prevent leishmaniasis has become a high prior-
ity. No less important than the choice of an antigen, the association of an appropriate adjuvant is necessary
to achieve a successful vaccination, as the majority of the tested antigens contain limited immunogenic
properties, and need to be supplemented with immune response adjuvants in order to boost their im-
munogenicity. However, few effective adjuvants that can be used against leishmaniasis exist on the market
today; therefore, it is possible to speculate that the research aiming to identify new adjuvants could be
considered relevant. Recently, Agaricus blazei extracts have proved to be useful in enhancing the immune
response to DNA vaccines against some diseases. This was based on the Th1 adjuvant activity of the
polysaccharide-rich fractions from this mushroom. In this context, the present study evaluated puriﬁed
fractions derived from Agaricus blazei as Th1 adjuvants through in vitro assays of their immune stimu-
lation of spleen cells derived from naive BALB/c mice. Two of the tested six fractions (namely F2 and
F4) were characterized as polysaccharide-rich fractions, and were able to induce high levels of IFN-γ, and
low levels of IL-4 and IL-10 in the spleen cells. The eﬃcacy of adjuvant action against L. infantum was
evaluated in BALB/c mice, with these fractions being administered together with a recombinant antigen,
LiHyp1, which was previously evaluated as a vaccine candidate, associated with saponin, against viscer-
al leishmaniasis (VL). The associations between LiHyp1/F2 and LiHyp1/F4 were able to induce an in vivo
Th1 response, which was primed by high levels of IFN-γ, IL-12, and GM-CSF, by low levels of IL-4 and
IL-10; as well as by a predominance of IgG2a antibodies in the vaccinated animals. After infection, the
immune proﬁle was maintained, and the vaccines proved to be effective against L. infantum. The immune
stimulatory effects in the BALB/c mice proved to be similar when comparing the F2 and F4 fractions with
a known Th1 adjuvant (saponin), though animals vaccinated with saponin did present a slight to mod-
erate inﬂammatory edema on their hind footpads. In conclusion, the F2 and F4 fractions appear to induce
a Th1-type immune response and, in this context, they could be evaluated in association with other pro-
tective antigens against Leishmania, as well as in other disease models.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Visceral leishmaniasis (VL) is mainly caused by two species of
parasites, the anthroponotic Leishmania donovani and the zoo-
notic L. infantum, for which a variety of canids serve as animal
reservoirs (Ready, 2014). The incidence of VL has been estimated
to be around 500,000 cases per year, with over 50,000 deaths world-
wide. Approximately 90% of the cases are registered in Bangladesh,
Brazil, Ethiopia, India, Nepal, and Sudan (Alvar et al., 2012). Addi-
tionally, in the nearly 98 countries that have reported the disease;
35 of them have already registered cases of VL and HIV co-infection
(World Health Organization, 2010).
The treatment of the disease is still based on the administra-
tion of pentavalent antimonial compounds; however, several side
effects registered in the patients, as well as the increased parasite
resistance to the drugs, have also caused serious problems (Croft
and Coombs, 2003; Minodier and Parola, 2010). Therefore, the de-
velopment of new strategies to prevent leishmaniasis has become
a high-priority (Costa et al., 2011; Lee et al., 2012).
The evidence of life-long immunity has inspired the develop-
ment of vaccination protocols against the disease, but few have
progressed beyond the experimental stage (Chávez-Fumagalli et al.,
2010; Coelho et al., 2003; Costa et al., 2014; Ramírez et al., 2013,
2014). In these studies, the type-1 cell-mediated immunity has
proven to be important as a protective response against leishmani-
asis. This response commonly depends on an IL-12-driven response,
leading to an IFN-γ and IL-2 production. Substantial up regulation
of inducible NO synthase by IFN-γ generates NO from splenic and
liver cells, thereby controlling parasite replication in these organs
(Carrión et al., 2006; Oliveira et al., 2011). In contrast, IL-4, IL-10,
IL-13, and TGF-β are major disease promoting cytokines, in turn
leading to the suppression of the Th1 response (Afonso and Scott,
1993; Martins et al., 2013). Thus, vaccines capable of inducing the
development of a Th1 immune response, primed by the produc-
tion of cytokines, such as IFN-γ and IL-12, and associated with low
levels of IL-4 and IL-10, could be considered promising candidates
to protect against the Leishmania sp. infection (Costa et al., 2014;
Fernandes et al., 2012).
Adjuvants of the immune response are deﬁned as products
capable of enhancing and/or changing an antigen-speciﬁc immune
response. Biotechnological advances have enabled modern vac-
cines to be based on the use of rationally designed recombinant
antigens associated with puriﬁed compounds as adjuvants, which
present a satisfactory safety proﬁle (Reed et al., 2013). Adjuvants
can be used for multiple purposes, such as to enhance the immu-
nogenicity of weak antigens, provide antigen-dose sparing to
accelerate the immune response, reduce the need for several im-
munizations, and/or increase the duration of protection (Petrovsky
and Aguilar, 2004). These products can be classiﬁed as immune
stimulatory molecules, such as toll-like receptor ligands and sa-
ponins, or delivery systems, such as aluminum salts, emulsions, and
lipid nanosystems (Fox et al., 2013).
The use of carbohydrates with adjuvant action is based on their
binding to innate immune receptors (Petrovsky and Cooper, 2011).
A number of carbohydrate compounds extracted from plants (Rajput
et al., 2007), bacteria (Koike et al., 1998), and yeast (Pillemer and
Ecker, 1941) have emerged as promising vaccine adjuvant candi-
dates. Their protective effects induced in immunotherapy have also
been proven to act against L. amazonensis (Yatawara et al., 2009),
L. donovani (Cook et al., 1982), and L. major (Al Tuwaijri et al., 1987).
In addition, carbohydrates’ adjuvant activity against L. donovani in
a golden hamstermodel has been registered (Cook et al., 1982; Obaid
et al., 1989). In parallel to the use of carbohydrates, the employ of
protein-bound polysaccharides has also been evaluated in a wide
range of biological applications (Maehara et al., 2012; Ooi and Liu,
2000), and recent studies have shown their use as immune adju-
vants (Engel et al., 2013).
Recently, our group demonstrated the in vitro (Valadares et al.,
2011) and in vivo antileishmanial activity of Agaricus blazei against
L. amazonensis and L. infantum (Valadares et al., 2012a, 2012b, re-
spectively). Compounds, such as β-glucans, tannins, glycoproteins,
and polysaccharides were characterized in this mushroom, which
maywell be responsible for the immunological activity of the fungus
(Bernardshaw et al., 2005; Gonçalves et al., 2012; Valadares et al.,
2012a). Taking this into account, in the present study, six
polysaccharide-rich fractions were puriﬁed from Agaricus blazei, and
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evaluated in in vitro experiments as inducers of the Th1 immune
response. The adjuvant fractions that presented the best results were
used in association with a recombinant antigen of L. infantum,
rLiHyp1 (Martins et al., 2013); and the subsequent vaccinewas evalu-
ated as regards the protection of BALB/c mice against L. infantum,
using saponin as a control.
2. Materials and methods
2.1. Ethics statement
Experiments were performed in compliance with the National
Guidelines, as set forth by the Institutional Animal Care (Law number
11.794, 2008), and the Committee on the Ethical Handling of Re-
search Animals from the Federal University of Minas Gerais (UFMG),
who approved this study under protocol number 067/2013.
2.2. Mice and parasites
Female BALB/c mice (8 weeks of age) were obtained from the
breeding facilities of the Department of Biochemistry and Immu-
nology, Institute of Biological Sciences (ICB), UFMG; and were
maintained under speciﬁc pathogen-free conditions. Experiments
were carried out using the L. infantum (MOM/BR/1970/BH46)
strain. Parasites were grown at 24 °C in Schneider’s medium
(Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Sigma-Aldrich), 20 mM
L-glutamine, 200 U/mL penicillin, and 100 μg/mL streptomycin, at
pH 7.4. The soluble Leishmania antigenic (SLA) extract was pre-
pared from 1 × 109 stationary-phase promastigotes, as described
(Coelho et al., 2003).
2.3. Puriﬁcation of polysaccharide-rich fractions from Agaricus
blazei
The technical protocol used to obtain the polysaccharide-rich
fractions from Agaricus blazei was adapted from Camelini et al.
(2005) and Meng et al. (2008). Brieﬂy, 20 g of fresh and dried
fruiting body of Agaricus blazei (Energy Vita®, lot #1, harvest in
2013) was macerated in 400 mL of ethanol 85% (v/v), with the
solution heated for 3 h at 80 °C. Next, the solution was ﬁltered in
a vacuum ﬁltration system using coarse ﬁlter paper, and the su-
pernatant was discarded. The pellet was dissolved in 350 mL
of distilled water, heated at 100 °C for 3 h, and then ﬁltered with a
vacuum ﬁltration system. Afterwards, 4 vol of ethanol PA (v/v)
was added. The solution was heated to above 80 °C to reduce the
ﬁnal volume, and the remaining solution was dialyzed with dis-
tilled water for 4 days, using membranes with the pore size of
40,000 Da. Afterwards, the solution was lyophilized to obtain the
total extract. Approximately 500 mg of the extract was dissolved
in 50 mL of deionized water, and the material was centrifuged at
12,500 × g for 30 min at 4 °C. The supernatant was collected and
further centrifuged at 37,500 × g for 40min, and then passed through
a 0.45 μM ﬁlter (Millipore®, Merck, Billerica, MA, USA). The collect-
ed supernatant was placed in a DEAE-Sepharose ion exchange
column, at which time six fractions were obtained and their car-
bohydrate content was determined using a phenol–sulphuric acid
spectrophotometric method (Dubois et al., 1956); the protein content
was determined using the Lowry method (Lowry et al., 1951);
and the phenol compound content was determined following the
Ainsworth method (Ainsworth and Gillespie, 2007). The technical
procedure was repeated three times, and the puriﬁed fractions
were stored at −80 °C until use.
2.4. Structural characterization of the best adjuvant fractions from
Agaricus blazei
The characterization of the fractions that presented the best in
vitro immune stimulation results was performed by FTIR spectros-
copy, and analyzed by transmittance IR spectroscopy, in the form
of KBr discs, using a Perkin Elmer Spectrum 1000 FTIR spectrom-
eter. 1H and 13C NMR spectra of solutions in D2O were recorded at
room temperature using a Fourier Transform Bruker Avance DRX
500 spectrometer, with an inverse multinuclear gradient probe-
head equipped with z-shielded gradient coils, together with Silicon
Graphics. The sodium 2,2-dimethylsilapentane-5-sulphonate (DSS)
was used as the internal standard for the experiments (0.00 ppm
for 1H).
2.5. Evaluation of the in vitro immune stimulation
Spleen cells obtained from BALB/c mice (n = 8) were collected,
pooled and in vitro cultured in 24-well plates (Nunc, Nunclon®,
Roskilde, Denmark), at 5 × 106 cells per mL, in duplicate. As a neg-
ative control, cells were incubated without any stimulus in complete
RPMI 1640 medium (Sigma-Aldrich), which was composed by
medium plus 10% FBS, 20mM L-glutamine, 200 U/mL penicillin, and
100 μg/mL streptomycin, at pH 7.4. The purpose was to evaluate the
cells’ natural stimulation by technical manipulation. In parallel, cells
were separately stimulated with each one of the six individual frac-
tions (100 μg per well, each one), or saponin (250 μg per well), for
48 h at 37 °C in 5% CO2. Cells were also stimulated with concana-
valin A (ConA; 5 μg per well), as a positive control (data not shown).
The IFN-γ, IL-4 and IL-10 levels were determined in the culture su-
pernatants, using commercial kits (BD OptEIA, Pharmingen, San
Diego, CA, USA), according to manufacturer’s instructions.
2.6. Immunization and challenge infection
After the evaluation of the in vitro immune stimulation results,
two (F2 and F4) of the six fractions were selected, based on their
capacity to induce a polarized Th1 immune response, and were
evaluated in association with the LiHyp1 protein. The recombi-
nant (rLiHyp1) protein was puriﬁed as described (Martins et al.,
2013). For the vaccination, BALB/c mice (n = 8, per group) were im-
munized subcutaneously in their left hind footpad with 25 μg of
rLiHyp1 associated with 25 μg of saponin (Quillaja saponaria bark
saponin, Sigma); or associatedwith 100 μg of F2 or F4. Other animals
received only adjuvants, the rLiHyp1 or diluent (saline). Three doses
were administered at 2-week intervals. Four weeks after the last
immunization, animals (n = 4, per group) were euthanized for the
analysis of the immune response elicited by vaccination. At the same
time, the remaining animals (n = 4, per group) were infected sub-
cutaneously in the right hind footpad with 1 × 107 stationary-
phase promastigotes of L. infantum. After 10 weeks, the animals were
euthanized, and the liver, spleen, bone marrow (BM), and paws’
draining lymph nodes (dLN) were collected to analyze the para-
site burden and evaluate the immune response. The vaccination
experiments were repeated twice, and presented similar results.
2.7. Estimation of parasite load
The liver, spleen, BM and dLN were collected from the euthan-
ized animals for parasite quantiﬁcation, following a limiting-
dilution technique (Coelho et al., 2003). Brieﬂy, organs were weighed
and homogenized using a glass tissue grinder in sterile PBS. Tissue
debris were removed by centrifugation at 150 × g, and cells were
concentrated by centrifugation at 2000 × g. Pellets were resus-
pended in 1 mL of Schneider’s insect medium supplemented with
20% FBS. Two hundred and twenty microliters was plated onto
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96-well ﬂat-bottom microtiter plates (Nunc), and diluted in log-
fold serial dilutions using supplemented Schneider’s medium, to a
10−1–10−12 dilution. Each sample was plated in triplicate and read
7 days after the beginning of the culture, at 24 °C. Pipette tips were
discarded after each dilution to avoid carrying adhered parasites from
one well to another. Results are expressed as the negative log of the
titer (i.e., the dilution corresponding to the last positive well) ad-
justed per microgram of tissue.
2.8. Cytokine production
Splenocyte cultures and cytokine assays were performed before
infection, and at 10th week after challenge, as described (Coelho
et al., 2003). Brieﬂy, single-cell preparations from spleen tissue were
plated in duplicate in 24-well plates (Nunc) at 5 × 106 cells/mL. Cells
were incubated in complete RPMI 1640 medium (non-stimulated,
negative control), or separately stimulated with SLA L. infantum
(25 μgmL−1) or rLiHyp1 (20 μgmL−1), at 37 °C in 5% CO2 for 48 h. IFN-γ,
IL-4, IL-10, IL-12, and GM-CSF levels were assessed in the super-
natants by a sandwich ELISA provided in commercial kits (BD OptEIA
TM set mouse IFN-γ, IL-4, IL-10, IL-12 and GM-CSF; Pharmingen,
USA); following manufacturer’s instructions. In order to block IL-
12, CD4+, and CD8+ mediated T cell cytokine release, spleen cells of
mice vaccinated and challenged were in vitro stimulated with SLA
L. infantum (25 μg mL−1), and incubated in the presence of 5 μg per
mL of monoclonal antibodies (mAb) against mouse IL-12 (C17.8),
CD4+ (GK 1.5), or CD8+ (53-6.7). Appropriate isotypes-matched con-
trols – rat IgG2a (R35-95) and rat IgG2b (95-1) – were employed
in the assays. Antibodies (no azide/low EndotoxinTM) were pur-
chased from BD (Pharmingen, USA).
2.9. Analysis of the humoral response
The rLiHyp1- or SLA L. infantum-speciﬁc IgG1 and IgG2a anti-
bodies were measured by ELISA, as described (Coelho et al., 2003).
Previous titration curves were performed to determine the most ap-
propriate antigen concentration, and antibody dilution to be used.
Brieﬂy, Falcon ﬂexible microtiter immunoassay plates (Becton
Dickinson) were coated with SLA L. infantum (1.0 μg per well) or
rLiHyp1 (1.0 μg per well), diluted in 100 μL coating buffer (50 mM
carbonate buffer) pH 9.6, for 18 h at 4 °C. After this, free binding sites
were blocked using 200 μL of PBS-T (phosphate buffer saline 1× plus
Tween 20 0.05%) buffer containing 5% casein for 1 h, at 37 °C. After
washing the plates 5 times using PBS-T, they were incubated with
100 μL of individual mice sera for 1 h at 37 °C. Samples were diluted
1:50 in PBS-T containing 0.5% casein solution. Plates were washed
5 times using PBS-T, and incubated with the peroxidase-labeled an-
tibodies speciﬁc to mouse IgG1 or IgG2a isotypes (Sigma Aldrich)
diluted at 1:5000, and incubated for 1 h at 37 °C. After washing 5
times with PBS-T, the reaction was developed through incubation
with H2O2, ortho-phenylenediamine and citrate-phosphate buffer
pH 5.0, for 30 min in the dark. The reaction was stopped by adding
25 μL H2SO4 2 N, and optical density was read in an ELISAmicroplate
spectrophotometer (Molecular Devices, Spectra Max Plus, Canada),
at 492 nm.
2.10. Statistical analysis
Statistical analysis was performed using the GraphPad Prism soft-
ware (version 6.0 for Windows). Results were expressed by
mean ± standard deviation (SD) of the groups. Outliers were evalu-
ated using the ROUT test and excluded from statistical analyses. The
normality analysis of the data was performed using the D’Agostino
and Pearson test. Statistical analysis of the results of immunized and/
or infected mice was performed by one-way analysis of variance
(ANOVA), using Tukey’s post-test for multiple comparisons between
the groups. Differences were considered signiﬁcant when P < 0.05.
Data presented in this study are representative of two indepen-
dent vaccination experiments, which presented similar results.
3. Results
3.1. Chemical characterization of the puriﬁed fractions from
Agaricus blazei and the in vitro selection of best adjuvant fractions
To select the polysaccharide-rich fractions derived from Agari-
cus blazei in order to perform the in vitro immune stimulation
experiments, the polysaccharide, protein, and phenolic com-
pound contents were determined, and the results are showed in
Fig. 1. The total extract of Agaricus blazei (ABP) was used as a pos-
itive control for the presence of these compounds. In evaluating the
protein content, only the F5 fraction presented high levels, whereas
the other fractions did not present signiﬁcant levels (Fig. 1A). In the
evaluation of the presence of carbohydrates, the F2, F3, and F4 frac-
tions presented the highest levels of its content, and were therefore
selected (Fig. 1B); however, upon evaluating the content of phe-
nolic compounds (Fig. 1C), it could be observed that the F3 fraction
presented the highest levels, and for this reason it was not se-
lected for the experiments. Fig. 1D shows the ratio between the
carbohydrate and protein levels of all of the fractions. Evaluating
the results, the F2 and F4 fractions were selected, as they pre-
sented the best results of polysaccharide content, andwere employed
in the in vitro experiments of immune stimulation.
To evaluate the in vitro immune stimulation of the two
polysaccharide-rich fractions obtained earlier, spleen cells taken from
naive BALB/c mice were collected, pooled, and separately stimu-
lated with each of the two puriﬁed fractions (F2 and F4), at which
time the IFN-γ, IL-4, and IL-10 levels were determined in the su-
pernatant cultures (Fig. 1E). Non-stimulated cells (only incubated
in medium) were used as a negative control, while the spleen cells
stimulated with saponin were used as a positive control. From the
results, it was possible to observe that both the F2 and F4 frac-
tions were able to stimulate a high production of IFN-γ, which was
associated with low levels of IL-4 and IL-10. The results of these
two fractions were similar to those found with the saponin stim-
ulus (Martins et al., 2013) and, in this context, these two fractions
were selected and evaluated as Th1 response adjuvants, in associ-
ation with the rLiHyp1 protein, as a vaccine against L. infantum.
3.2. Structural characterization of adjuvant fractions using 1H NMR
and 13C NMR spectroscopy
In an attempt to characterize the selected fractions structural-
ly, FTIR spectra of the fractions were taken, and the results are
presented as a Supplementary ﬁgure (Fig. S1). Although the F2 and
F4 fractions had been characterized as rich-polysaccharide frac-
tions, they present some differences in their chemical contents. Thus,
F2 fraction possesses a higher degree of carbohydrates and phe-
nolic compounds than the F4 fraction. This last fraction presents a
higher degree of proteins, in comparison to F2 fraction. Like a rep-
resentative analysis, data derived from the F4 fraction were showed
(Fig. S1). In their analysis, the main attributions of the absorption
peaks reveal characteristic glycosidic structures: OH stretching
(3000–3500 cm−1), CO stretching (1022 cm−1), C—O—C stretching
(1162 cm−1), and anomeric C1H group vibration (1082 cm−1). The
protein attributions were observed with characteristic absorption
peaks at 1649, 1413 (characteristic absorption bands related to car-
boxylate anion), and 1242 cm−1. These attributions suggest the
presence of a protein–glucans complex (Fig. S1A). The 1H NMR spec-
trum obtained from the F4 fraction is also shown (Fig. S1B). The
anomeric region and the other carbon protons in beta-conﬁguration
were observed. The 1H chemical shifts in the anomeric region are
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observed between 4 and 6 ppm. Signals at 4.1 and 4.5 ppm were
observed corresponding to the beta-conﬁguration and in the region
between 4.9 and 5.6 ppm, corresponding to alpha-conﬁguration. The
chemical shifts from 3.3 to 4.0 ppm were assigned to the protons
of carbons C2–C6 of the glycosidic ring. The attributions observed
at 0.5–3.0 ppm were considered to be from proteins, given that the
N—CH3 and N—H groups are generally found within this range. The
13C NMR spectrum of the F4 fraction is also shown here (Fig. S1C).
The assignments of the representative peaks of carbohydrates in-
cluded: anomeric carbon (C1) signals of glycosides assigned to
approximately 105 ppm, and C2–C6 from the glycosidic ring as-
signed to 70–80 ppm. The intensity of signals reveals that the
polysacarides of the fractions are constituted by β-glucans.
3.3. Immunogenicity of rLiHyp1 protein associated or not with
saponin, F2 or F4 fractions
The immunogenicity of rLiHyp1 protein associated with the F2
or F4 fractions, or saponin, as well as administered alone, was evalu-
ated in BALB/c mice; 4 weeks after the last vaccine dose, and before
the challenge infection (Fig. 2). Spleen cells from mice vaccinated
with rLiHyp1/F2, rLiHyp1/F4, or rLiHyp1/saponin produced signiﬁ-
cantly higher levels of IFN-γ, IL-12, and GM-CSF than did those
secreted by spleen cells from all control groups (saline, F2, F4,
saponin, or rLiHyp1 groups), following in vitro stimulation with
recombinant protein. In this context, rLiHyp1/F2, rLiHyp1/F4, or
rLiHyp1/saponin groups produced signiﬁcantly higher levels of these
Fig. 1. Chemical characterization of the puriﬁed fractions from Agaricus blazei and their evaluation as stimulant immune response agents. The total contents of proteins
(A), carbohydrates (B), and phenolic compounds (C) of the six puriﬁed fractions are shown. The ratio between the carbohydrate and protein levels is also shown (D). Spleen
cell suspensions were obtained from BALB/c mice and were either non-stimulated (negative control) or separately stimulated with each individual fraction (100 μg per well)
or with saponin (250 μg per well), for 48 h at 37 °C and 5% CO2. The IFN-γ, IL-4, and IL-10 levels were measured in the culture supernatants by means of ELISA capture and
are illustrated here (E). Each bar represents the mean ± standard deviation (SD) of the cytokine levels, which were obtained from three independent experiments, all of
which presented similar results.
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cytokines in comparison to the saline group (***P < 0.0001), as an
infection control; as well as in relation to the rLiHyp1 group, as an
adjuvant’ eﬃcacy control (+++P < 0.0001). In addition, no signiﬁ-
cant difference in the IL-4 and IL-10 production could be observed
in any group, after stimulation with the rLiHyp1 protein (Fig. 2A).
The ratio between IFN-γ/IL-4 and IFN-γ/IL-10 levels, as well as
between IL-12/IL-4 and IL-12/IL-10 levels, showed that vacci-
nated animals with rLiHyp1/F2, rLiHyp1/F4, or rLiHyp1/saponin
presented a predominant Th1 response after LiHyp1-stimulus (Fig. 2B
and C, respectively). Moreover, in these vaccinated animals, the
rLiHyp1-speciﬁc antibody production was predominantly found in
the IgG2a isotype (Fig. 2D). No signiﬁcant difference in the cytokine
or antibody production could be observed between the rLiHyp1/F2,
rLiHyp1/F4, and rLiHyp1/saponin groups.
3.4. Protective eﬃcacy against L. infantum
Evaluating if the immunization with rLiHyp1 protein associ-
ated with F2, F4, or saponin adjuvants was able to induce a Th1
response in the vaccinated animals and protect against challenge
infection, this study investigated whether or not the vaccination
would, in fact, protect against L. infantum. For this, after the three
vaccine doses, an infection was performed and the animals were
followed-up over a 10-week period, at which time the parasite
burden was evaluated and expressed as the negative log of the titer
in the liver, spleen, dLN, and BM of the vaccinated and infected
animals (Fig. 3). In the results, reductions in the number of para-
sites were observed in all of the evaluated organs in the vaccinated
mice with rLiHyp1/F2, rLiHyp1/F4, or rLiHyp1/saponin, when com-
pared to the control groups (saline, F2, F4, saponin, and rLiHyp1
groups). In this context, vaccinatedmicewith rLiHyp1/F2, when com-
pared to the saline and F2 groups, presented reductions in the
parasite load in the liver (3.2 and 2.7-log reductions, respectively;
Fig. 3A), spleen (2.2 and 2.0-log reductions, respectively; Fig. 3B),
dLN (2.6 and 2.1-log reductions, respectively; Fig. 3C), and BM (2.5
and 2.3-log reductions, respectively; Fig. 3D). In addition, vacci-
natedmicewith rLiHyp1/F4, when compared to saline and F4 groups,
presented reductions in the parasite load in the liver (4.0 and 3.1-
log reductions, respectively; Fig. 3A), spleen (3.1 and 2.8-log
reductions, respectively; Fig. 3B), dLN (4.1 and 3.3-log reductions,
respectively; Fig. 3C), and BM (4.2 and 3.0-log reductions, respec-
tively; Fig. 3D). In the same manner, immunized mice with
rLiHyp1/saponin, when compared to the saline and rLiHyp1 groups,
presented reductions in the parasite load in the liver (3.8 and
Fig. 2. Cellular and humoral response induced in BALB/c mice by immunization with rLiHyp1 associated with F2 or F4 fractions, or with saponin. Single cell suspensions
were obtained from the spleen of mice, 4 weeks after the last vaccination. Cells were only incubated and non-stimulated (negative control) or stimulated with rLiHyp1
(20 μg mL−1), for 48 h at 37 °C in 5% CO2. IFN-γ, IL-12, GM-CSF, IL-4, and IL-10 levels were measured in culture supernatants by capture ELISA (A), using commercial kits
(Pharmingen, San Diego, CA, USA). Each bar represents the mean ± standard deviation (SD) of data from four individual mice per group. The ratios between the IFN-γ/IL-10
and IFN-γ/IL-4 levels (B), as well as between the IL-12/IL-10 and IL-12/IL-4 levels (C) were calculated and also showed. Additionally, the ratio between LiHyp1-speciﬁc IgG1
and IgG2a antibodies was obtained for sera of each individual mouse within their respective vaccination group. Statistically signiﬁcant differences were observed between
the rLiHyp1/F2, rLiHyp1/F4 or rLiHyp1/saponin groups, when compared to saline (***P < 0.0001) and rLiHyp1 (+++P < 0.0001) groups (D).
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2.6-log reductions, respectively), spleen (2.8 and 2.1-log reduc-
tions, respectively), dLN (3.7 and 2.7-log reductions, respectively),
and BM (3.3 and 2.3-log reductions, respectively).
In all cases, the results showed the protection induced by rLiHyp1
protein against L. infantum, when associated with a Th1 adjuvant,
as previously described (Martins et al., 2013). No difference
could be observed in the parasite burden between the rLiHyp1/F2,
rLiHyp1/F4, and rLiHyp1/saponin groups. In addition, the immu-
nization with rLiHyp1, without adjuvant, was unable to induce
protection against L. infantum, demonstrating the necessity of the
association of immune adjuvants to vaccine candidates against
leishmaniasis.
3.5. Cellular and humoral responses elicited after infection
The cytokine production in the supernatants of spleen cell cul-
tures stimulated with SLA was analyzed 10 weeks after infection
(Fig. 4). Spleen cells derived frommice vaccinated with rLiHyp1/F2,
rLiHyp1/F4, or rLiHyp1/saponin produced signiﬁcantly higher levels
of SLA-speciﬁc IFN-γ, IL-12, and GM-CSF cytokines, than did those
secreted by spleen cells from control groups (saline, F2, F4, saponin,
and rLiHyp1 groups; Fig. 4A). By contrast, the SLA-driven produc-
tion of IL-4 and IL-10 showed that vaccination with the rLiHyp1
protein associated with F2 or F4 fractions, or saponin, induced very
low levels of these cytokines in the vaccinated and infected animals.
The ratio between IFN-γ/IL-4 and IFN-γ/IL-10 levels (Fig. 4B), as well
as between the IL-12/IL-4 and IL-12/IL-10 levels (Fig. 4C), indi-
cated that these animals had developed a Th1 response. Using the
rLiHyp1 protein as a stimulus, the Th1 proﬁle was also main-
tained after the infection (data not shown). In the antibody
production, it was possible to observe that vaccinated mice with
rLiHyp1/F2, rLiHyp1/F4, or rLiHyp1/saponin, and infected mice pre-
sented a predominance of SLA-speciﬁc IgG2a isotypes, which was
signiﬁcantly higher than the IgG1 levels (Fig. 4D). This proﬁle could
also be observed when using rLiHyp1 as an antigen in the experi-
ments (data not shown).
The present study evaluated the contribution of CD4+ and CD8+
T cells, as well as the dependence of IL-12 production for the SLA-
speciﬁc IFN-γ production from the spleen cells of mice immunized
with rLiHyp1/F2, rLiHyp1/F4, or rLiHyp1/saponin and infected with
L. infantum (Fig. 5). The IFN-γ production was signiﬁcantly sup-
pressed using anti-CD4 or anti-IL-12 monoclonal antibodies in the
spleen cell cultures derived from mice vaccinated with rLiHyp1/
saponin (Fig. 5A), rLiHyp1/F2 (Fig. 5B), or rLiHyp1/F4 (Fig. 5C).
Evaluating the results, it could be observed that the addition of anti-
CD8 antibodies in the cultures decreased the IFN-γ production, as
compared to the control cell cultures without treatment; however,
the obtained levels of this cytokine were higher in relation to the
values encountered after the use of anti-CD4 or anti-IL-12 anti-
bodies in both vaccinated groups. These results suggest that CD8+
cells were not directly involved in the IFN-gamma secretion in the
present study.
Fig. 3. Protection of BALB/c mice vaccinated with rLiHyp1 associated with either saponin or F2 or F4 fractions against L. infantum. Mice inoculated with saline, saponin, F2,
F4, rLiHyp1, rLiHyp1/saponin, rLiHyp1/F2 or rLiHyp1/F4 were subcutaneously infected with 1 × 107 stationary-phase promastigotes of L. infantum. The number of parasites
in the liver (A), spleen (B), paws’ draining lymph nodes (C), and bone marrow (D) was measured, 10 weeks after challenge, using a limiting-dilution technique. Mean ± stan-
dard deviation (SD) of four mice in each group is shown. Statistically signiﬁcant differences in the parasite load were observed in all evaluated organs between the rLiHyp1/F2,
rLiHyp1/F4, and rLiHyp1/saponin groups, when compared to saline (***P < 0.0001) and rLiHyp1 (+++P < 0.0001) groups. Data shown are representative of two independent
experiments, which presented similar results.
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4. Discussion
Visceral leishmaniasis is one of the main neglected tropical par-
asite diseases, presenting a high mortality, ranking only behind
malaria in the number of victims (Alvar et al., 2012). As the pro-
tection against re-infection with L. major in murine models is
possible, efforts have been performed to develop a protective vaccine;
however, to date, no effective vaccine has been created (Fernandes
et al., 2012). An important advantage in using vaccines based on
attenuated pathogens, inactivated viruses, and/or bacteria is based
on the fact that they are suﬃciently immunogenic, without the need
to associate additional adjuvants (Coler et al., 2007; Costa et al., 2011).
However, the use of these candidates would present disadvan-
tages, mainly due to the diﬃculty in standardization and large-
scale production (Handman, 2001). By contrast, protein-based
vaccines, although offering considerable advantages in terms of safety
and production costs, are less immunogenic and must be supple-
mented with immune response adjuvants, in order to boost their
immunogenicity (Cerpa-Cruz et al., 2013).
In this context, for the development of a successful vaccine, the
association of a good adjuvant is desirable. Some studies have evalu-
ated products containing this immune activity, such as interleukin-12
(Coelho et al., 2003), granulocyte macrophage-colony stimulating
factor (Badaró et al., 1994), bacille Calmette-Guérin (Misra et al., 2001),
montanide ISA 720 (Tonui et al., 2004), aluminum salts (Misra
et al., 2001), monophosphoryl lipid A (Coler et al., 2007), CpG
oligodeoxynucleotides (Stacey and Blackwell, 1999), liposomes (Kahl
et al., 1989), glucans (Holbrook et al., 1981), Corynebacterium parvum
(Carvalho et al., 2007), saponins (Giunchetti et al., 2007), and Freund’s
adjuvant (Panaro et al., 2001).
Adjuvants classiﬁed as immune stimulatory molecules present
their mechanism of action based on the activation of innate im-
munity receptors expressed in antigen presenting cells (APCs), such
as macrophages and dendritic cells, which take up and present the
antigens to T helper cells. Such receptors are used by APCs to detect
pathogen-associated molecular patterns (PAMPs), called patho-
gen recognition receptors (PRRs) (O’Hagan and de Gregorio, 2009).
Likewise, a previous study showed that fruiting bodies of Agaricus
blazei present immune stimulatory activity inmice by activating CD4+
T cells, natural killer (NK) cells, and phagocytes, as well as by in-
creasing the production of pro-inﬂammatory cytokines, such as IFN-γ
and TNF-α, using these receptors (Gonçalves et al., 2012). The authors
observed that spleen cells of animals exhibited a higher radioac-
tivity of 99mTecnecium-labeled leukocytes, whichwas associatedwith
Fig. 4. Analysis of the cellular and humoral response in BALB/c mice after L. infantum infection. Single cell suspensions were obtained from the spleens of mice, 10 weeks
after infection. Cells were non-stimulated (negative control) or stimulated with SLA L. infantum (25 μg mL−1), for 48 h at 37 °C in 5% CO2. Levels of IFN-γ, IL-12, GM-CSF, IL-4
and IL-10 were measured in culture supernatants by capture ELISA. Mean ± standard deviation (SD) of the cytokine levels determined in four individual mice per group is
shown (A). The ratios between IFN-γ/IL-10 and IFN-γ/IL-4 levels (B), and between the IL-12/IL-10 and IL-12/IL-4 levels (C), are showed. Additionally, the ratio between SLA-
speciﬁc IgG1 and IgG2a isotype antibody levels was calculated for sera of each individual mouse within their respective vaccination group (D). In all cases, statistically signiﬁcant
differences were observed between the rLiHyp1/F2, rLiHyp1/F4 or rLiHyp1/saponin groups, when compared to saline (***P < 0.0001) and rLiHyp1 (+++P < 0.0001) groups.
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an increased number of CD4+ T cells in the spleen of the animals.
In addition, the frequency of activated monocytes and neutrophils
was increased in the blood of the Agaricus blazei-treated animals
(Gonçalves et al., 2012).
More recently, one Agaricus blazei extract proved to be useful in
enhancing the immune response to DNA vaccines against some dis-
eases, such as hepatitis B (Wang et al., 2010), and foot-and-mouth
disease (Chen and Shao, 2006); while a polysaccharide-rich frac-
tion derived from thismushroompresented a Th1 adjuvant activity
(Cui et al., 2013). In the present study, a technical protocol was per-
formedusing anAgaricus blazei total extract, fromwhich six fractions
were obtained. These productswere evaluated in relation to the pres-
ence of proteins, polysaccharides, and phenolic compounds; and two
of whichwere characterized as polysaccharide-rich fractions. Based
on data described in the literature, these two fractions were used
for the in vitro immune stimulation of spleen cells fromnaive BALB/c
mice, and bothwere able to induce a speciﬁc and selectively higher
production of IFN-γ, which was associated with low levels of IL-4
and IL-10; and the results were similar to those obtained using
saponin.
Studies employing the mouse model have led to the character-
ization of the immune mechanisms necessary to develop organ
speciﬁc immune responses, which would clear the parasites from
the liver, but not from the spleen (Carrión et al., 2006). BALB/c mice
infectedwith L. donovani or L. chagasi/L. infantum are themost widely
studied models of VL, but they are also considered to be rather vul-
nerable. In the murine VL, C57BL/6 mice mount an early Th1
response, which prevents the further growth of the parasite, in turn
producing a self-healing phenotype (Lehmann et al., 2000). In ad-
dition, the respective resistance and susceptibility of C57BL/6 and
BALB/c strains depend not only on the Th1 and Th2 types of immune
responses from CD4+ T cells, but also on the genetic background from
the hosts (Afonso and Scott, 1993). For this reason, it is important
to evaluate the immune response induced in inbred mouse strains.
In this context, in the present study, spleen cells derived from naive
mice were used to evaluate the in vitro immune stimulation, in order
to select only the candidates that would be able to subvert the unde-
sirable Th2 proﬁle in a susceptible mouse strain.
Additionally, in vaccine studies, immunogens are administered
in association with Th1-type adjuvants and, after only a few weeks,
mice are infected and followed-up for about 2 or 3 months
(Chávez-Fumagalli et al., 2010; Costa et al., 2014; Martins et al.,
2013). In this time, spleen cells are collected and cultured in vitro
with the antigens used in the immunization protocols, and/or
with Leishmania extracts, in order to evaluate their immunogenic-
ity. At this point, the levels of cytokines, such as IFN-γ and IL-12,
markers of the Th1 response, and IL-4 and IL-10, indicators of Th2
response, are determined and, together with the results of the
parasite burden, the eﬃcacy of the immunogens is determined
(Costa et al., 2014).
In relation to the protective eﬃciency, the present study de-
scribed the eﬃcacy of the association between an antigen derived
from L. infantum, LiHyp1, which was recently shown as a protec-
tive antigen against this parasite species (Martins et al., 2013),
and two adjuvant fractions, F2 and F4, in an attempt to verify if
these compounds could, in fact, increase the immunogenicity of
the rLiHyp1. The association between rLiHyp1 and both fractions
was able to induce an in vivo Th1 response in the vaccinated
animals, which was primed by production of high levels of IFN-γ,
IL-12, and GM-CSF; as well as by low levels of IL-4 and IL-10.
Additionally, a predominance of IgG2a isotype antibodies could
be observed in these animals, facts that could have contributed to
protecting the animals against the infection. More importantly,
the F2 and F4 fractions presented similar results in relation to
those vaccinated with saponin, although animals vaccinated with
saponin have presented a slight to moderate inﬂammatory edema
in their vaccinated footpads. This fact was not observed when F2
or F4 fractions were used with rLiHyp1 or administered alone.
Immunization using the rLiHyp1 protein without an adjuvant was
unable to induce protection against infection, emphasizing the
need for the association of antigens with an effective adjuvant, as
also described in other studies concerning other evaluated anti-
gens (Coelho et al., 2003; Costa et al., 2014; Martins et al., 2013;
Ramírez et al., 2014; Zanin et al., 2007).
The present study also demonstrates that the association between
rLiHyp1 and F2 or F4 fractions in the vaccinated animals induced
a decrease in the production of IL-4 and IL-10. Very low levels of
parasite-speciﬁc IL-10 were detected after the stimulation of spleen
cells derived from vaccinatedmice, 10 weeks after infection. By con-
trast, spleen cells from the control mice showed a signiﬁcantly higher
Fig. 5. Involvement of IL-12, CD4+ and CD8+ T cells in the IFN-γ production after L. infantum challenge. Single cell suspensions were obtained from the spleens of mice vac-
cinated with rLiHyp1/saponin (A), rLiHyp1/F2 (B) or rLiHyp1/F4 (C), 10 weeks after infection. Cell cultures were stimulated with SLA L. infantum (25 μg mL−1) in the absence
(positive control) or in the presence of monoclonal antibodies (mAb) against mouse IL-12 (C17.8), CD4+ (GK 1.5), or CD8+ (53-6.7), at a concentration of 5 μg/mL, each one;
for 48 h at 37 °C in 5% CO2. Levels of IFN-γ were measured in culture supernatants by capture ELISA. Appropriate isotype-matched controls – rat IgG2a (R35-95) and rat
IgG2b (95-1) – were employed in the assays. Antibodies (no azide/low EndotoxinTM) were purchased from BD (Pharmingen, San Diego, CA, USA). Mean ± standard deviation
(SD) of the IFN-γ levels determined in four individual mice per group is shown. Statistically signiﬁcant differences between non-treated control cells and cultures incubated
with anti-CD4, anti-CD8 or anti-IL-12 monoclonal antibodies were observed (***P < 0.0001).
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production of this cytokine. Indeed, the control of the parasite-
mediated IL-10 response may be critical for protection, since this
cytokine is considered to be the most important factor for VL pro-
gression inmice treatedwith an anti-IL-10 receptor antibody (Murray
et al., 2002), or after infection with Leishmania in IL-10 deﬁcient mice
(Murphy et al., 2001). In BALB/c mice, IgG1 levels are associated with
disease progression into some Leishmania species, such as L. infantum
(Martins et al., 2013) and L. amazonensis (Coelho et al., 2003). In the
present study, immunized mice produced higher levels of
Leishmania-speciﬁc IgG2a antibodies, as compared to IgG1 levels,
also demonstrating the development of a Th1 immune response in
these animals. As observed in the IFN-γ and IL-12 production, spleen
cells from vaccinated mice produced higher levels of GM-CSF, a
cytokine related to macrophage activation and resistance in murine
models against intracellular pathogens, such as L. infantum
(Chávez-Fumagalli et al., 2010), L. major (Dumas et al., 2003), and
L. donovani (Murray et al., 1995).
As regards the proﬁle of T cells involved in IFN-γ production,
CD4+ T cells proved to be the major source of this cytokine in the
protected mice, since the depletion of these cells in the cultures
of spleen cells stimulated with SLA signiﬁcantly diminished this
response. Although previous reports have shown that the activa-
tion of both CD4+ and CD8+ cell subsets may be important for the
killing of parasites in vaccinated mice using several parasite re-
combinant antigens (Chávez-Fumagalli et al., 2010; Costa et al.,
2014; Martins et al., 2013), the present study’s data suggest that
CD8+ cells may contribute to a lesser extent to the induction of an
IFN-γ-mediated response elicited by immunization using the rLiHyp1
protein, when the immunogen was evaluated in association with
different adjuvants.
As a result of research into the development of vaccines against
canine VL in the world, Brazil has become one of the countries in
which commercial vaccines for the immunization of dogs are avail-
able. Two vaccines, Leishmune® (Parra et al., 2007) and Leish-Tec®
(Fernandes et al., 2014), use saponin as an adjuvant in their com-
positions. Saponins, natural glycosides derived from steroid or
triterpene, exhibited different biological and pharmacological ac-
tivities. Notably, they can activate the mammalian immune system,
which has led to their use as adjuvants. Their unique capacity to
stimulate both the Th1 immune response and the production of
cytotoxic T-lymphocytes makes the saponins ideal for use in vaccine
compositions, in order to protect against intracellular pathogens,
such as Leishmania (Rajput et al., 2007). Saponins have been used
successfully for veterinary applications (Dalsgaard, 1987; Kensil et al.,
1991), but are considered toxic for use in humans. In relation to
their toxicity, saponins can cause local and granulomatous reac-
tions; hemolysis, reﬂecting their aﬃnity to cholesterol present in
erythrocyte membranes; and local pain (Goldenthal et al., 1993;
Kensil et al., 1991). As Agaricus blazei is considered as a nutraceutic,
and its use is permitted in humans due to the absence of toxicity;
and due to the fact that both F2 and F4 fractions were puriﬁed
from this mushroom, without being associated with non-natural
compounds, these products could well be considered for use in
humans.
In conclusion, the results of the present study showed the pu-
riﬁcation and identiﬁcation of Th1 adjuvants derived from Agaricus
blazei, as well as their application in BALB/c mice, in association with
the rLiHyp1 protein, to protect against VL. The associations between
rLiHyp1/F2 and rLiHyp1/F4 induced a speciﬁc Th1 immune re-
sponse, which was primed by production of high levels of IFN-γ,
IL-12, and GM-CSF, as well as by low levels of IL-4 and IL-10. In ad-
dition, the immunogens proved to be protective against L. infantum.
Therefore, it can be concluded that, in addition to their uses in other
disease models, the F2 and F4 fractions could also be used as Th1
adjuvants in association with other antigens to protect against the
Leishmania sp. infection.
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